Regeneron (REGN) PT Lowered to $728 at Truist Securities, Competitive Pressure on Praluent and Eylea Cited
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $728.00 (from $754.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
